Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$0.22
-$0.03(-2.80%)
At close: 4:00 PM EST
$0.22
-$0.03(-2.80%)
Day’s Range― - ―
52-Week Range$1.31 - $18.90
Previous CloseN/A
Volume36.45K
Average Volume (3M)746.19K
Market Cap
$6.35M
Enterprise Value-$1.95M
Total Cash (Recent Filing)$4.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 19, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.78
Shares Outstanding2,188,469
10 Day Avg. Volume779,793
30 Day Avg. Volume746,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap-0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.79K
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$7.00Price Target Upside3081.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage (no Debt)Zero reported debt materially reduces refinancing and interest-rate risk for a clinical-stage biotech. That structural balance-sheet strength preserves optionality to fund R&D or negotiate licensing terms without immediate interest obligations, supporting multi‑month development planning.
Completed Azora Merger And Committed FinancingThe merger is a structural change: it brings Azora assets and up to $64M committed financing to fund AT177 development. That financing and asset infusion materially extend runway and repositions the company into inflammatory disease, altering the long‑term asset base and strategic focus.
Bolstered R&D Leadership And Board ExpertiseAdding experienced drug developers and an R&D leader strengthens clinical execution and molecule selection capabilities. Durable improvement in development governance and trial design raises the probability of efficient advancement of AT177 and makes the company more credible to partners and investors.
Bears Say
Pre-revenue With Sustained LossesOperating without product revenue means the company must fund operations externally until commercialization. Persistent multi‑million dollar losses signal structural dependence on capital markets or partners, increasing execution risk if fundraising conditions tighten over the next several months.
Negative Operating And Free Cash Flow (cash Burn)Consistent negative operating and free cash flow creates structural funding requirements. Even with improvement versus prior years, ongoing burn constrains discretionary R&D spending and forces dependence on dilutionary financing or milestones, which can delay programs or change strategic priorities.
Equity Decline And Dilution / Complex New Capital StructureThe new Series A preferred shares, conversion terms, executive inducement grants and governance changes are structural and can dilute common holders or shift control. That altered capital structure increases long‑term dilution risk and may complicate future financings or partner negotiations.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $1.31 and its highest was $18.90 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Adial Pharmaceuticals Inc’s market cap is $6.35M.
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is Aug 19, 2026 which is in 43 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on May 11, 2026. The company reported -$1.48 earnings per share for the quarter, beating the consensus estimate of -$2.73 by $1.25.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -1.02.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 2,188,469 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$1.48 in its last earnings report, beating expectations of -$2.73. Following the earnings report the stock price went up 0.699%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$7.00
▲(3081.82% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
35.44% Insiders
0.29% Mutual Funds
0.09% Other Institutional Investors
64.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---